Drugs in MeSH Category Hormones

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xeris	GVOKE PFS	glucagon	SOLUTION;SUBCUTANEOUS	212097-002	Sep 10, 2019		RX	Yes	Yes	9,649,364		Y
Xeris	GVOKE HYPOPEN	glucagon	SOLUTION;SUBCUTANEOUS	212097-004	Sep 10, 2019		RX	Yes	Yes	11,590,205		Y
Lupin Ltd	GLUCAGON	glucagon	INJECTABLE;INJECTION	214457-001	Jul 22, 2025	AP	RX	No	No
Amphastar Pharms Inc	CORTROSYN	cosyntropin	INJECTABLE;INJECTION	016750-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes
Xeris	GVOKE VIALDX	glucagon	SOLUTION;INTRAVENOUS	212097-006	Mar 14, 2025		RX	Yes	Yes

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Hormones

Last updated: January 24, 2026

Summary

This report provides a comprehensive analysis of the market landscape and patent environment surrounding drugs classified under the NLM MeSH (Medical Subject Headings) class: Hormones. It delineates key market drivers, competitive positioning, patent filing trends, intellectual property (IP) strategies, and regulatory influences shaping this sector. The insights aim to assist stakeholders—pharmaceutical companies, investors, and policymakers—in strategic decision-making.

---

What is the Scope of Drugs in the Hormones NLM MeSH Class?

The NLM MeSH classification encompasses a broad range of hormone-related pharmaceuticals, including:

Subclasses	Examples	Therapeutic Focus
Peptide hormones	Insulin, Glucagon	Diabetes, metabolic disorders
Steroid hormones	Estrogen, Testosterone, Cortisol	Endocrine disorders, hormone replacement therapy (HRT), reproductive health
Others	Parathyroid hormone, Melatonin	Osteoporosis, sleep disorders

Major categories are:

• Insulins and related antidiabetics
• Estrogens and progestins
• Androgens and anabolic steroids
• Corticosteroids
• Thyroid hormones

---

Market Dynamics: Key Drivers and Trends

1. Demographic and Epidemiological Influences

• Incidence of chronic diseases: Rising prevalence of diabetes (especially type 2), osteoporosis, and hormonal deficiencies drive demand.
• Aging Population: Globally aging populations (EU: 19%, US: 16% over 65 years [2]) increase hormone therapy needs.
• Lifestyle shifts: Obesity and metabolic syndrome contribute to increased demand for insulin and steroid hormones.

2. Technological Innovation

• Biologic drugs: Biopharmaceutical advances in recombinant DNA technology have improved drug efficacy and safety, particularly for insulin and recombinant hormones.
• Personalized medicine: Pharmacogenomics tailor hormone therapies, fostering innovation.
• Delivery systems: Development of insulin pumps, transdermal patches, and sustained-release formulations enhances patient adherence.

3. Competitive Landscape and Market Share

Top Market Players (2022)	Estimated Market Share	Key Products
Novo Nordisk	45%	Levemir, Tresiba, Ozempic
Eli Lilly	25%	Humalog, Trulicity
Sanofi	10%	Lantus
Other (Biocon, Biogen)	20%	Varied

Note: The insulin segment dominates roughly 60% of the hormone market, with rapid growth in GLP-1 receptor agonists segments.

4. Regulatory Environment and Market Access

• Stringent approval processes by FDA, EMA, and other agencies influence time-to-market.
• Patent exclusivity periods (generally 20 years from filing) are crucial for market dominance.
• Data exclusivity and biosimilar entry regulations impact generics and biosimilars’ competition.

5. Pricing and Reimbursement Policies

• High drug prices, especially for insulins and biologics, attract regulatory scrutiny.
• Countries exhibit diverse reimbursement frameworks influencing market access, e.g., US (private and public payers), EU (state-funded programs).

6. Emerging Markets and Global Expansion

• Rapid healthcare infrastructure growth in Asia-Pacific (e.g., China, India) expands accessible patient populations.
• Local manufacturing and patent filings are increasing, impacting global patent landscapes.

---

Patent Landscape: Current Trends and Analysis

1. Patent Filing Trends (2010–2022)

Year	Number of Patents Filed	Major Applicants	Focus Areas
2010–2014	1,200	Novo Nordisk, Eli Lilly, Sanofi	Insulin formulations, delivery systems
2015–2018	1,500	Same + Emerging Biotech firms	GLP-1 analogs, conjugates
2019–2022	2,000	Increasing diversity	Biosimilars, alternative delivery, novel formulations

Sources: Patent databases (WIPO PATENTSCOPE, EPO Espacenet)

2. Patent Types and Focus

Patent Type	Primary Focus	Implication
Composition patents	Novel hormone formulations	Market exclusivity
Delivery patents	Pumps, patches, microspheres	Improved adherence and efficacy
Manufacturing patents	Recombinant production methods	Cost-efficient and scalable production
Use patents	New therapeutic indications	Market expansion

3. Key Patent Holders and Strategic Movements

Applicant	Number of Patents (2022)	Strategic Focus
Novo Nordisk	150	Long-acting insulins, GLP-1s, delivery systems
Eli Lilly	120	Insulin analogs, biosimilars
Sanofi	80	Insulin formulations, hormonal conjugates
Emerging biotech	50+	Novel hormone mimetics, gene therapies

Note: Patent filings increasingly emphasize biologics, biosimilars, and drug delivery innovations.

4. Patent Expiry and Lifecycle Management

• Many blockbuster hormones patents expire between 2025–2030.
• Companies increasingly file follow-on patents (secondary patents) to extend exclusivity.
• Patent litigation and patent thickets hinder generic/biosimilar activities.

5. Geographic Patent Filing Patterns

Region	Most Active Entities	Key Focus
United States	Lilly, Novo Nordisk, Amgen	Biologics, biosimilars
Europe	Sanofi, Novo Nordisk	Innovative formulations
China	Local firms & multinationals	Cost-effective production, local innovations
India	Local biotech companies	Generics, biosimilars

---

Comparison: Hormone Drug Market vs. Other Endocrine Therapeutics

Aspect	Hormone Drugs (Focus of this report)	Other Endocrine Drugs
Market Size (2022)	Approx. $50 billion	$30 billion
Patent Strategy	Heavy focus on biologics and formulations	Small-molecule dominance
Innovation Area	Biologics, delivery, personalized therapy	Symptom management, diagnostics
Generics Entry	Stricter due to biologics complexity	Easier, more prevalent

---

Regulatory and Policy Influences

• The Biologics Price Competition and Innovation Act (BPCIA) (US, 2009) facilitates biosimilar entry, impacting patent landscapes.
• European Medicines Agency (EMA) emphasizes biosimilarity and refillable patents.
• Patent linkage systems (e.g., in India) delay generic approvals, affecting market dynamics.

---

FAQs

Q1: How do biologic patent protections differ from small-molecule hormone drugs?
Biologics generally enjoy 12-year data exclusivity in the US, whereas small-molecules typically have 20-year patent terms. Biosimilar development involves complex patent challenges, leading to longer litigation periods.

Q2: What is the impact of biosimilars on the hormone market?
Biosimilars threaten the revenues of originator biologics, prompting companies to develop second-generation products and extend patent protections through secondary patents.

Q3: How do patent strategies differ between large pharmaceutical companies and biotech startups?
Large firms focus on broad composition and process patents to maintain dominance, while startups often pursue niche indications or delivery innovations to carve market segments.

Q4: Which regions have the most active patent filings in hormone drugs?
The US and Europe lead due to high R&D investment and patent protections; China and India are rapidly increasing filings, mainly targeting generics and biosimilars.

Q5: What role does regulatory policy play in the patent landscape?
Regulatory exclusivity and patent linkage delay generic entry, influence patent filing strategies, and determine market viability, especially in emerging markets.

---

Key Takeaways

• Market Drivers: Rising prevalence of chronic endocrine disorders, aging populations, and technological advances underpin growth prospects.
• Patent Landscape: Dominated by biologics, with strategic patent filings extending product lifecycles; biosimilars threaten ongoing revenues.
• Competition: Top players (Novo Nordisk, Eli Lilly, Sanofi) maintain dominance via broad patent portfolios; emerging biotech firms focus on innovation and delivery mechanisms.
• Regulatory Impact: Policies influence patent strategy, biosimilar entry, and pricing dynamics; patent expirations around 2025–2030 will reshape competitive landscapes.
• Emerging Opportunities: Personalized therapies, drug delivery systems, and biosimilars present growth avenues amid patent expirations and regulatory evolutions.

---

References

[1] National Library of Medicine. (2022). MeSH Browser: Hormones.

[2] United Nations, Department of Economic and Social Affairs. (2022). World Population Ageing 2022.

[3] IQVIA. (2022). The Global Use of Medicines Report.

[4] WIPO Patent Database. (2022). Trends in Hormone Drug Filings.

[5] European Medicines Agency. (2022). Guidelines on biosimilar products.

[6] US Food and Drug Administration. (2022). Biological Product Patent Certifications.

---

This structured analysis delivers critical insights into the current state and future outlook of hormone drugs within the patent landscape, guiding strategic planning and investment decisions.